An 80-year-old man was referred to our hospital for further examination of abnormalities in a blood count. A full blood count showed thrombocytopenia and blasts were found in a peripheral blood film. Bone marrow aspiration revealed a mild hyperplasia with erythroid predominance, trilineage dysplasia, and the presence of 18.3% blasts. A diagnosis of myelodysplastic syndrome with excess blasts was made. He had received 75 mg/m2 subcutaneous azacitidine for 5 days in a 35-day cycle. He had taken apixaban 2.5 mg twice daily for stroke prevention and vonoprazan fumarate 10 mg once daily. The patient had maintained stable disease by the administration of azacitidine.
[IMAGE OMITTED. SEE PDF.]
During 14th cycle of azacitidine, he complained with abdominal pain. Aluminium hydroxide gel and magnesium hydroxide relieved his symptom. However, it was exacerbated after the administration of azacitidine in each cycle. Anorexia was also accompanied. Physical examination of his abdomen showed no tenderness. Blood analysis showed the following: haemoglobin concentration, 128 g/L; white blood cell count, 3.8 × 109/L (2% stab cells, 60% segmental cells, 30% lymphocytes, 5% monocytes, 1% eosinophils, and 2% basophils); platelet count, 91 × 109/L; and C-reactive protein, 1.2 mg/L at the start of 16th cycle. Upper gastrointestinal endoscopy was performed for further investigation on Day 4 in 16th cycle. Surprisingly, appearance of patchy and linear redness was expanded from gastric cardia to gastric lower body (left and middle). A gastric biopsy specimen demonstrated normal epithelium in gastric mucosa, and haemorrhage and haemosiderin deposition in the lamina propria (right). Because gastric mucosal haemorrhage following azacitidine was suspected, we discontinued administrating azacitidine while continuing to take apixaban and vonoprazan fumarate. Thereafter, the pain disappeared, and he regained his appetite. Although the endoscopic appearance remained unchanged after 1, 2, and 7 months of 16th cycle of azacitidine, it was almost completely disappeared after 21 months. Moreover, he has maintained stable disease after discontinuation of azacitidine.
Diffuse gastric mucosal haemorrhage is very rare. Azacitidine-associated hemorrhagic event is suspected in the present case, but the mechanism of haemorrhage following azacitidine is still unknown. Besides, we consider that the cause of haemorrhage is not associated with neither thrombocytopenia due to azacitidine, direct oral anticoagulant nor other factors. Elucidation of the mechanism contributing to bleeding is important issue in patients managed by azacitidine.
AUTHOR'S CONTRIBUTIONConception and design: H. Kitamura, K. Miyahara, and Y. Kubota. Acquisition of data: H. Kitamura, K. Miyahara, R. Tomimasu, and M. Miyahara. Analysis of data: H. Kitamura and K. Miyahara.
Interpretation of data: H. Kitamura, K. Miyahara, Y. Kubota, S. Kimura, and M. Miyahara. Writing-original draft: H. Kitamura, K. Miyahara, and Y. Kubota. Writing-review and editing: H. Kitamura, K. Miyahara, Y. Kubota, R. Tomimasu, S. Kimura, and M. Miyahara.
INFORMED CONSENTThe patient provided written informed consent.
CONFLICT OF INTERESTThe authors declare no conflict of interest.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details


1 Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan
2 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan